Your scan report says “hepatic steatosis,” your doctor says lose some weight, and a coworker mentions that a peptide called tesamorelin “melts liver fat.” You do not have HIV, which is the only group the drug is approved for. So did anyone test it in people like you, and did the liver actually get healthier?
Someone did. A Massachusetts General Hospital team ran a one-year, placebo-controlled trial of prescription tesamorelin in 51 adults with obesity and fatty liver who did not have HIV, and posted the results on ClinicalTrials.gov in November 2025. The liver fat reading moved in the right direction, but the biopsy scores that track inflammation and scarring did not change.
What the one-year trial measured
Adults aged 18 to 65 joined if they had a body mass index of 30 or more (25 or more if they already had steatohepatitis) and fat in the liver confirmed by biopsy or by a specialized MRI-based scan called proton spectroscopy. Heavy drinkers and people with active hepatitis B or C infection were excluded. Participants were randomly assigned to daily tesamorelin shots or identical placebo shots for 12 months, and neither they nor the study staff knew who got which. After that year, everyone was offered the real drug for six more months.
Of 26 people who started on tesamorelin and 25 on placebo, 19 in each group finished the blinded year. Liver fat on the scan was available for 18 and 16 of them.
Liver fat fell; biopsy scores held still
The registry lists the median change in liver fat fraction as minus 5.3 percent with tesamorelin and plus 3.6 percent with placebo. The ranges reported around those medians overlapped, and the posted record does not include a statistical test, so the size and certainty of that gap cannot be judged from the registry alone.
The repeat biopsies are the part that matters most for long-term liver health. The median change in the NAFLD activity score, which grades fat, inflammation and cell injury, was zero in both groups. The median change in fibrosis stage, the scarring that can lead to cirrhosis, was also zero in both groups. The investigators noted in the registry that not everyone had inflamed or scarred liver at the start, and that the biopsy group was small, which limits what these numbers can show.
Other measures were small. LDL cholesterol dipped slightly more on tesamorelin, and C-reactive protein, a marker of inflammation, changed little in either group. Side effects leaned toward the drug: joint pain in 6 of 26 on tesamorelin versus 1 of 25 on placebo, swelling in 6 versus 1, and injection-site stinging in 8 versus 1.
The idea came from earlier work by the same group in people with HIV. A six-month trial of 50 patients, published in JAMA in 2014, found modest drops in liver fat on tesamorelin and a short-lived rise in fasting blood sugar during the first weeks. A larger one-year HIV trial reported in 2019 found that more people on tesamorelin got their liver fat below the usual cutoff for fatty liver.
The new results suggest the scan effect may carry over to people without HIV, but they do not show that the liver tissue itself improved over a year. We found no journal article reporting these results in PubMed as of October 2026, so no peer-reviewed interpretation is available yet.
These trials used prescription tesamorelin (Egrifta) under medical supervision. Research-catalog products labeled for laboratory use are not the drug these trials tested and carry no human evidence of their own for fatty liver.
What does help a fatty liver
The National Institute of Diabetes and Digestive and Kidney Diseases says losing 3 to 5 percent of body weight can cut liver fat, and 7 to 10 percent may be needed to reduce inflammation and scarring. Physical activity helps even without weight loss, and gradual loss is safer than crash dieting. In 2024 the FDA approved Rezdiffra for adults with steatohepatitis and moderate to advanced scarring who do not have cirrhosis, used along with diet and exercise.
If tesamorelin comes up, ask your doctor which outcome you are trying to change, liver fat on a scan or scarring on a biopsy or elastography test, because this trial moved one and not the other. Not medical advice.
Sources
- ClinicalTrials.gov: Growth hormone releasing hormone analog to improve nonalcoholic fatty liver disease, posted results (NCT03375788)
- Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA, 2014 (PubMed)
- Stanley TL et al. Randomised trial of tesamorelin for fatty liver disease in people with HIV. Lancet HIV, 2019 (PubMed)
- NIDDK: Treatment for NAFLD and NASH
- FDA: FDA approves first treatment for patients with liver scarring due to fatty liver disease (2024)
Related reading
- Tesamorelin Lowered Liver Fat in a Small HIV Trial, With Open Questions
- Tesamorelin Outside HIV: A Slightly Smaller Waist and No Weight Loss
- Egrifta Targets HIV Lipodystrophy Fat, Not General Weight Loss
By The Everyday Brief. AI-assisted drafting with automated source and editorial checks. Sources fetched 2026-10-24 PT. Not medical advice.